Few medicines have a more improbable origin story than ivermectin. It began not in a pharmaceutical laboratory but in a bag of ordinary soil, collected by a Japanese scientist who believed that the answer to some of humanity's oldest parasitic diseases might already be present in the ground beneath his feet. This article traces that discovery from soil sample to Nobel Prize, explains honestly how the drug works and what it has actually been shown to do, and distinguishes clearly between its well-established uses and claims that have not held up under rigorous testing.
A Soil Sample and a Patient Scientist
In the 1970s, Dr. Satoshi Ōmura, a microbiologist at Japan's Kitasato Institute, ran a systematic program of collecting soil samples from across the country, then culturing the bacteria found within them to see what chemical compounds those microorganisms produced. This was painstaking, unglamorous work. Soil bacteria, particularly the genus Streptomyces, have long been a rich natural source of medically useful compounds, since these organisms produce antimicrobial substances to compete against other microbes in the same patch of earth. It is a small but genuine illustration of a created order in which the world contains, ready for discovery, remedies for conditions that afflict the living.
Among thousands of soil samples, one collected near a golf course in Kawana, in Shizuoka Prefecture, yielded a previously unidentified strain of Streptomyces, later named Streptomyces avermitilis. Ōmura's laboratory isolated and cultured dozens of promising strains and shipped them to a research partner in the United States for biological testing, since Kitasato did not have the capacity to screen for antiparasitic activity at scale.
From Bacterium to Medicine: The Merck Partnership
That research partner was the Merck Institute for Therapeutic Research, where Dr. William C. Campbell, an Irish-born parasitologist, led a screening program testing the biological activity of compounds from Ōmura's cultures. Campbell's team tested extracts against parasitic worms in mice, using a rodent nematode infection as a screening model. One extract, derived from the Kawana soil culture, showed striking activity: it cleared the parasitic worms from infected animals far more effectively than existing compounds.
The active substance was named avermectin. Merck's chemists then modified its structure slightly to improve potency and reduce toxicity, producing a semi-synthetic derivative called ivermectin. This is worth pausing on, because it is sometimes described loosely: ivermectin itself is not found in nature. It is a chemically modified version of a natural compound, refined through conventional pharmaceutical chemistry, in the same tradition as many other drugs derived from bark, mold or soil organisms. The underlying discovery, however, belonged to nature and to the patience of scientists willing to look for it.
Ivermectin was first brought to market in 1981 as a veterinary antiparasitic, transforming livestock and companion animal medicine by controlling roundworms, heartworms and other parasites with a single, low-toxicity treatment. Its extension to human medicine followed soon after.
How Ivermectin Works, and Why It Is Safe for Mammals
Ivermectin's mechanism explains both its power against parasites and its favorable safety profile in people. The drug binds to glutamate-gated chloride ion channels, which are found in the nerve and muscle cells of invertebrates such as nematode worms and arthropods (mites, lice). This binding increases the cell's permeability to chloride ions, causing sustained hyperpolarization of the cell membrane. The practical effect is paralysis of the parasite's muscles and pharynx, followed by death of the organism.
Mammals, including humans, do not have glutamate-gated chloride channels of this type, which is one reason ivermectin does not paralyze human nerve and muscle tissue at therapeutic doses. Ivermectin does have some affinity for related mammalian chloride channels in the central nervous system, but under normal circumstances it cannot reach them in meaningful concentrations, because the P-glycoprotein pump at the blood-brain barrier actively exports the drug out of the brain. This is why standard oral doses are well tolerated in most patients, though it also explains why certain animals bred with a mutation in this pump gene (some collie-type dogs, for example) can experience serious toxicity at doses that are safe for other mammals.
A Global Health Legacy: River Blindness and Beyond
The clearest and best-documented human benefit of ivermectin has been in the fight against onchocerciasis, commonly called river blindness, a disease caused by the parasitic worm Onchocerca volvulus and transmitted by blackflies in parts of sub-Saharan Africa and Latin America. Left untreated, chronic infection causes intense itching, skin disease, and progressive blindness. Clinical trials in the 1980s demonstrated that a single annual or semi-annual oral dose of ivermectin dramatically reduced the density of microfilariae (larval worms) in the skin and eyes, halting progression of the disease.
In 1987, Merck made an unusual and consequential decision: it committed to donate ivermectin free of charge, in whatever quantity was needed, for as long as needed, to combat river blindness. This became the Mectizan Donation Program, run in partnership with the World Health Organization, national health ministries and nongovernmental organizations. Over subsequent decades, billions of treatments have been distributed, and onchocerciasis has been eliminated as a public health problem in several countries in Latin America and reduced dramatically across much of Africa. Ivermectin is also a mainstay treatment for lymphatic filariasis (elephantiasis) as part of combination mass drug administration programs, and it is an approved treatment for strongyloidiasis, a soil-transmitted intestinal roundworm infection, and for scabies, a mite infestation of the skin, in both oral and topical formulations.
This record deserves to be stated plainly: it is one of the more successful humanitarian medical partnerships of the modern era, grounded in decades of controlled clinical trials, epidemiological surveillance and sustained public health infrastructure, not in a single breakthrough moment.
The 2015 Nobel Prize
In October 2015, the Nobel Assembly at the Karolinska Institute awarded the Nobel Prize in Physiology or Medicine jointly to three scientists. Half the prize went to Tu Youyou, a Chinese pharmaceutical chemist, for her discovery of artemisinin, a treatment for malaria derived from the sweet wormwood plant. The other half was shared by William C. Campbell and Satoshi Ōmura, "for their discoveries concerning a novel therapy against infections caused by roundworm parasites." The Nobel committee's citation recognized the two men's combined contribution: Ōmura's systematic isolation of novel Streptomyces strains, and Campbell's insight in identifying and developing the antiparasitic properties of the resulting compound into a usable medicine. The committee noted that the impact of ivermectin on human health, particularly in the developing world, had been immeasurable, citing its role in nearly eliminating several devastating parasitic diseases.
The award was notable for honoring basic, unglamorous microbiological fieldwork alongside applied pharmaceutical chemistry, and for recognizing that some of the most consequential medical advances arise slowly, from unglamorous screening programs conducted over years, rather than from singular flashes of insight.
What Ivermectin Is, and Is Not, Approved to Treat
It is worth being precise here, because ivermectin's reputation has become entangled with claims well beyond its established uses. In the United States and most other jurisdictions, ivermectin (in tablet form) is approved for treating strongyloidiasis and onchocerciasis; topical formulations are approved for head lice and rosacea. It is not approved for the treatment or prevention of viral infections, including COVID-19.
During the COVID-19 pandemic, laboratory studies, including work from Monash University in Australia published in 2020, showed that ivermectin could inhibit viral replication in cell culture. That is a genuine finding, but it came with an important caveat that the same researchers acknowledged: the concentrations required to achieve that effect in a laboratory dish were far higher than what can be safely achieved with approved doses in the human body. Subsequent randomized controlled trials in actual patients, including the TOGETHER trial conducted in Brazil and published in the New England Journal of Medicine in 2022, found no significant reduction in hospitalization or disease progression among COVID-19 patients treated with ivermectin compared with placebo. Regulatory agencies, including the FDA and EMA, have concluded that current evidence does not support its use for this purpose outside of clinical trials.
None of this diminishes what ivermectin has genuinely accomplished. It simply means that good medicine requires distinguishing between what has been demonstrated in a petri dish, what has been shown in animals, and what has held up in well-conducted human trials. Patients considering ivermectin for any purpose, on-label or otherwise, should discuss the actual evidence with their own physician, who can weigh their individual history and circumstances. Informed consent means understanding both what a medicine has proven to do and what it has not.
Key takeaway: Ivermectin's journey from a Japanese soil sample to a Nobel Prize reflects both the genuine wonders latent in the natural world and the discipline required to prove, through years of careful trials, exactly what a medicine can and cannot do.